• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

核糖醇与紫草素的协同作用促进乳腺癌细胞凋亡。

Synergistic Effect of Ribitol and Shikonin Promotes Apoptosis in Breast Cancer Cells.

作者信息

Doddapaneni Ravi, Tucker Jason D, Lu Pei J, Lu Qi L

机构信息

McColl-Lockwood Laboratory for Muscular Dystrophy Research, Cannon Research Center, Carolinas Medical Center, Atrium Health, Charlotte, NC 28203, USA.

出版信息

Int J Mol Sci. 2025 Mar 15;26(6):2661. doi: 10.3390/ijms26062661.

DOI:10.3390/ijms26062661
PMID:40141303
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11942206/
Abstract

The mortality rate of breast cancer remains high, despite remarkable advances in chemotherapy. Therefore, it is imperative to identify new treatment options. In the present study, we investigated whether the metabolite ribitol enhances the cytotoxic effect of shikonin against breast cancer in vitro. Here, we screened a panel of small molecules targeting energy metabolism against breast cancer. The results of the study revealed that ribitol enhances shikonin's growth-inhibitory effects, with significant synergy. A significant ( < 0.01) increase in the percentage (56%) of apoptotic cells was detected in the combined treatment group, compared to shikonin single-treatment group (38%), respectively. The combined ribitol and shikonin treatment led to significant arrest of cell proliferation (40%) ( < 0.01) compared to untreated cells, as well as the induction of apoptosis. This was associated with upregulation of p53 ( < 0.05) and downregulation of c-Myc ( < 0.01), Bcl-xL ( < 0.001), and Mcl-1 ( < 0.05). Metabolomic analysis supports the premise that inhibition of the Warburg effect is involved in shikonin-induced cell death, which is likely further enhanced by dysregulation of glycolysis and the tricarboxylic acid (TCA) cycle, afflicted by ribitol treatment. In conclusion, the present study demonstrates that the metabolite ribitol selectively enhances the cytotoxic effect mediated by shikonin against breast cancer in vitro.

摘要

尽管化疗取得了显著进展,但乳腺癌的死亡率仍然很高。因此,确定新的治疗方案势在必行。在本研究中,我们调查了代谢物核糖醇是否能增强紫草素在体外对乳腺癌的细胞毒性作用。在此,我们筛选了一组针对乳腺癌能量代谢的小分子。研究结果表明,核糖醇可增强紫草素的生长抑制作用,具有显著的协同作用。与紫草素单药治疗组(38%)相比,联合治疗组检测到凋亡细胞百分比显著(<0.01)增加(56%)。与未处理的细胞相比,核糖醇和紫草素联合治疗导致细胞增殖显著停滞(40%)(<0.01),并诱导细胞凋亡。这与p53上调(<0.05)以及c-Myc(<0.01)、Bcl-xL(<0.001)和Mcl-1(<0.05)下调有关。代谢组学分析支持这样的前提,即抑制瓦尔堡效应参与了紫草素诱导的细胞死亡,核糖醇处理导致的糖酵解和三羧酸(TCA)循环失调可能进一步增强了这种作用。总之,本研究表明,代谢物核糖醇在体外能选择性增强紫草素介导的对乳腺癌的细胞毒性作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34f0/11942206/f9a7fbde90a6/ijms-26-02661-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34f0/11942206/a49ae389eee7/ijms-26-02661-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34f0/11942206/7b942fe3c079/ijms-26-02661-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34f0/11942206/2a51e68d6748/ijms-26-02661-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34f0/11942206/b4268b4a80e6/ijms-26-02661-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34f0/11942206/1da046b91439/ijms-26-02661-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34f0/11942206/4deca7a14cd5/ijms-26-02661-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34f0/11942206/f9a7fbde90a6/ijms-26-02661-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34f0/11942206/a49ae389eee7/ijms-26-02661-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34f0/11942206/7b942fe3c079/ijms-26-02661-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34f0/11942206/2a51e68d6748/ijms-26-02661-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34f0/11942206/b4268b4a80e6/ijms-26-02661-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34f0/11942206/1da046b91439/ijms-26-02661-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34f0/11942206/4deca7a14cd5/ijms-26-02661-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34f0/11942206/f9a7fbde90a6/ijms-26-02661-g007.jpg

相似文献

1
Synergistic Effect of Ribitol and Shikonin Promotes Apoptosis in Breast Cancer Cells.核糖醇与紫草素的协同作用促进乳腺癌细胞凋亡。
Int J Mol Sci. 2025 Mar 15;26(6):2661. doi: 10.3390/ijms26062661.
2
Metabolic Reprogramming by Ribitol Expands the Therapeutic Window of BETi JQ1 against Breast Cancer.核糖醇介导的代谢重编程拓宽了BETi JQ1治疗乳腺癌的治疗窗口。
Cancers (Basel). 2023 Sep 1;15(17):4356. doi: 10.3390/cancers15174356.
3
Targeting Cell Necroptosis and Apoptosis Induced by Shikonin via Receptor Interacting Protein Kinases in Estrogen Receptor Positive Breast Cancer Cell Line, MCF-7.通过受体相互作用蛋白激酶靶向紫草素诱导雌激素受体阳性乳腺癌细胞系MCF-7中的细胞坏死性凋亡和凋亡
Anticancer Agents Med Chem. 2018;18(2):245-254. doi: 10.2174/1871520617666170919164055.
4
ER-mediated anti-tumor effects of shikonin on breast cancer.紫草素通过内质网介导的抗肿瘤作用对乳腺癌的影响。
Eur J Pharmacol. 2019 Nov 15;863:172667. doi: 10.1016/j.ejphar.2019.172667. Epub 2019 Sep 20.
5
Effect of shikonin on human breast cancer cells proliferation and apoptosis in vitro.紫草素对人乳腺癌细胞体外增殖和凋亡的影响。
Yakugaku Zasshi. 2006 Dec;126(12):1383-6. doi: 10.1248/yakushi.126.1383.
6
RIP1K and RIP3K provoked by shikonin induce cell cycle arrest in the triple negative breast cancer cell line, MDA-MB-468: necroptosis as a desperate programmed suicide pathway.紫草素引发的RIP1K和RIP3K在三阴性乳腺癌细胞系MDA-MB-468中诱导细胞周期停滞:坏死性凋亡作为一种绝望的程序性自杀途径。
Tumour Biol. 2016 Apr;37(4):4479-91. doi: 10.1007/s13277-015-4258-5. Epub 2015 Oct 26.
7
Synergy between sublethal doses of shikonin and metformin fully inhibits breast cancer cell migration and reverses epithelial-mesenchymal transition.亚致死剂量的紫草素与二甲双胍协同作用可完全抑制乳腺癌细胞迁移并逆转上皮间质转化。
Mol Biol Rep. 2022 Jun;49(6):4307-4319. doi: 10.1007/s11033-022-07265-9. Epub 2022 May 7.
8
Shikonin Inhibits the Proliferation of Human Breast Cancer Cells by Reducing Tumor-Derived Exosomes.紫草素通过减少肿瘤来源的外泌体抑制人乳腺癌细胞的增殖。
Molecules. 2016 Jun 16;21(6):777. doi: 10.3390/molecules21060777.
9
Shikonin inhibits the Warburg effect, cell proliferation, invasion and migration by downregulating PFKFB2 expression in lung cancer.紫草素通过下调肺癌中 PFKFB2 的表达抑制瓦博格效应、细胞增殖、侵袭和迁移。
Mol Med Rep. 2021 Aug;24(2). doi: 10.3892/mmr.2021.12199. Epub 2021 Jun 10.
10
Anticancer Efficacy of Targeted Shikonin Liposomes Modified with RGD in Breast Cancer Cells.载药靶向紫草素脂质体修饰 RGD 对乳腺癌细胞的抗癌作用。
Molecules. 2018 Jan 29;23(2):268. doi: 10.3390/molecules23020268.

引用本文的文献

1
Mitochondrial metabolic reprogramming in colorectal cancer: mechanisms of resistance and future clinical interventions.结直肠癌中的线粒体代谢重编程:耐药机制与未来临床干预措施
Cell Death Discov. 2025 Aug 9;11(1):375. doi: 10.1038/s41420-025-02670-y.
2
Plant metabolites and functional foods in metastatic breast cancer: a supportive strategy for management.植物代谢产物与功能性食品在转移性乳腺癌中的作用:一种辅助治疗策略
Front Pharmacol. 2025 Jul 23;16:1631232. doi: 10.3389/fphar.2025.1631232. eCollection 2025.

本文引用的文献

1
Effect and mechanisms of shikonin on breast cancer cells in vitro and in vivo.体外和体内紫草素对乳腺癌细胞的作用及机制。
BMC Complement Med Ther. 2024 Nov 8;24(1):389. doi: 10.1186/s12906-024-04671-3.
2
Breast cancer statistics 2024.2024 年乳腺癌统计数据。
CA Cancer J Clin. 2024 Nov-Dec;74(6):477-495. doi: 10.3322/caac.21863. Epub 2024 Oct 1.
3
Altered metabolism in cancer: insights into energy pathways and therapeutic targets.癌症中的代谢改变:能量途径和治疗靶点的新见解。
Mol Cancer. 2024 Sep 18;23(1):203. doi: 10.1186/s12943-024-02119-3.
4
Exploring treatment options in cancer: Tumor treatment strategies.探索癌症的治疗选择:肿瘤治疗策略。
Signal Transduct Target Ther. 2024 Jul 17;9(1):175. doi: 10.1038/s41392-024-01856-7.
5
Shikonin in breast cancer treatment: a comprehensive review of molecular pathways and innovative strategies.紫草素在乳腺癌治疗中的应用:分子途径及创新策略的全面综述。
J Pharm Pharmacol. 2024 Aug 2;76(8):967-982. doi: 10.1093/jpp/rgae041.
6
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.2022 年全球癌症统计数据:全球 185 个国家和地区 36 种癌症的发病率和死亡率全球估计数。
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
7
Unveiling the mechanisms and challenges of cancer drug resistance.揭示癌症药物耐药性的机制和挑战。
Cell Commun Signal. 2024 Feb 12;22(1):109. doi: 10.1186/s12964-023-01302-1.
8
Improved efficacy of FKRP AAV gene therapy by combination with ribitol treatment for LGMD2I.通过与核糖醇联合治疗肢带型肌营养不良2I型(LGMD2I)提高FKRP腺相关病毒(AAV)基因治疗的疗效。
Mol Ther. 2023 Dec 6;31(12):3478-3489. doi: 10.1016/j.ymthe.2023.10.022. Epub 2023 Nov 2.
9
Metabolic Reprogramming by Ribitol Expands the Therapeutic Window of BETi JQ1 against Breast Cancer.核糖醇介导的代谢重编程拓宽了BETi JQ1治疗乳腺癌的治疗窗口。
Cancers (Basel). 2023 Sep 1;15(17):4356. doi: 10.3390/cancers15174356.
10
Apoptotic cell death in disease-Current understanding of the NCCD 2023.疾病中的细胞凋亡性死亡——2023 年对 NCCD 的最新理解。
Cell Death Differ. 2023 May;30(5):1097-1154. doi: 10.1038/s41418-023-01153-w. Epub 2023 Apr 26.